How should rifabutin be dosed for Mycobacterium avium complex treatment and prophylaxis in HIV‑infected patients with CD4 <50 cells/µL, and how do CYP3A4 inhibitors, macrolide antibiotics, and contraindications (e.g., pregnancy, CYP3A4 inducers) modify the regimen?

Rifabutin Dosing for MAC in HIV-Infected Patients

For MAC prophylaxis in HIV-infected patients with CD4 <50 cells/µL, use rifabutin 300 mg orally once daily, but macrolides (clarithromycin or azithromycin) are now preferred first-line agents. 1

Primary Prophylaxis Dosing

Standard Regimen

• Rifabutin 300 mg PO daily for patients with CD4 <50 cells/µL 1, 2
• Continue lifelong unless disseminated MAC develops requiring treatment 3
• Alternative: 150 mg twice daily with food if gastrointestinal intolerance occurs 2

Important Context

While rifabutin was the first FDA-approved MAC prophylaxis agent in 1992 3, clarithromycin or azithromycin are now preferred over rifabutin due to superior efficacy and fewer drug interactions 1. Rifabutin reduces MAC bacteremia by approximately 50% 3, but macrolides are more effective and better tolerated.

Dose Adjustments for Drug Interactions

With Protease Inhibitors (CYP3A4 Inhibitors)

• With indinavir, nelfinavir, or amprenavir: Reduce rifabutin to 150 mg daily (half dose) 1
• With ritonavir: Reduce rifabutin to 150 mg every other day or three times weekly (quarter dose) 1
• With hard-gel saquinavir: Do NOT use rifabutin 1
• Avoid with protease inhibitors when possible due to complex interactions 1

With Non-Nucleoside Reverse Transcriptase Inhibitors

• With efavirenz: Increase rifabutin to 450 mg daily 1
• With delavirdine: Do NOT use rifabutin 1
• With nevirapine: Insufficient data; avoid if possible 1

With Macrolide Antibiotics

Critical warning: When rifabutin is combined with clarithromycin or azithromycin (for MAC treatment, not prophylaxis), the risk of uveitis increases substantially 2. This occurred in 24 of 63 patients (38%) receiving rifabutin 600 mg daily with clarithromycin 4. The combination of clarithromycin plus rifabutin for prophylaxis is not recommended as it offers no additional benefit and increases adverse effects 1.

MAC Treatment Dosing (Not Prophylaxis)

When disseminated MAC develops:

• Every regimen must contain clarithromycin or azithromycin as the backbone 3
• Add ethambutol as second agent 3
• Rifabutin may be added as third agent at reduced doses when combined with macrolides 3
• In the Canadian trial, rifabutin 300 mg daily (reduced from 600 mg due to uveitis) with clarithromycin and ethambutol was effective 4

Contraindications and Precautions

Absolute Contraindications

• Active tuberculosis (must be ruled out before starting rifabutin to prevent rifampin resistance) 1, 5
• Hypersensitivity to rifamycins 2

Relative Contraindications/Cautions

• Pregnancy: Limited data, but anecdotal experience with rifampin (related drug) has not shown adverse outcomes; use only if benefit outweighs risk 1
• Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% if toxicity suspected 2
• Hepatic impairment: Mild impairment requires no adjustment; moderate-to-severe impairment data lacking 2

Before Starting Rifabutin

• Rule out active MAC disease with clinical assessment ± blood culture 3
• Rule out active tuberculosis with chest X-ray and tuberculin skin test 3
• Consider drug interaction profile with current antiretrovirals 1

Key Adverse Effects to Monitor

Common (>1%)

• Uveitis: Rare at 300 mg monotherapy, but increases dramatically with higher doses or when combined with fluconazole/macrolides 2
  • If uveitis develops: Temporarily discontinue rifabutin, obtain ophthalmology evaluation, treat with corticosteroids/mydriatics
  • May restart if mild; discontinue permanently if symptoms recur 2
• Neutropenia (25% vs 20% placebo) 2
• Discolored urine (30% of patients - benign) 2
• Rash (11%) 2
• GI upset (nausea 6%, diarrhea 3%) 2

Serious but Rare

• Thrombocytopenia, hepatitis, severe cutaneous reactions (DRESS, SJS, TEN) 2

Discontinuation of Prophylaxis

Stop rifabutin prophylaxis when CD4 count rises to >100 cells/µL for >3 months on antiretroviral therapy 5. This reduces pill burden and drug interactions without increasing MAC risk. Restart if CD4 drops below 50 cells/µL 5.

Clinical Pitfalls

1. Don't use rifabutin as first-line prophylaxis: Macrolides are superior 1
2. Don't combine clarithromycin + rifabutin for prophylaxis: No added benefit, more toxicity 1
3. Don't forget dose adjustments with antiretrovirals: Failure to reduce rifabutin dose with protease inhibitors causes uveitis 1
4. Don't start without ruling out TB: Risk of inducing rifampin resistance 1, 5
5. Monitor for uveitis aggressively when using higher doses or combinations 2